Pharma major Dr Reddy’s Laboratories has launched Clopidogrel tablets in the US market with 180-days exclusivity.

The tablets are a bioequivalent generic version of Plavix of Bristol Myers Squibb and Sanofi SA, a blood thinner drug.

The Hyderabad-based company was among the first applicants to submit a substantially complete Abbreviated New Drug Application for Clopidogrel tablets in 300 mg capacity and was awarded 180 days of marketing exclusivity, according to a release.

The Plavix brand had US sales of approximately $6.740 billion for the most recent 12 months ended March 31, 2012, according to IMS Health.

(This article was published on May 18, 2012)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.